FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVA	4L
OMB Number:	3235-0287
Estimated average burde	n hours
per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type I	tesponses)														
1. Name and Address of Reporting Person *- Klump Michael A (East) (First) (Middle) 1111 MAIN STREET, SUITE 660 (Street) VANCOUVER, WA 98660				Issuer Name and Ticker or Trading Symbol CytoDyn Inc. [CYDY] Date of Earliest Transaction (Month/Day/Year) 10/08/2019 If Amendment, Date Original Filed(Month/Day/Year)						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
			4. If A						_X_ Form						
								Folii							
(City)		(State)	(Zip)		Table I - Non-Derivative Securities Acqu					Acquired, Di	nired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Y	ear) any		on Date, if	3. Transact Code (Instr. 8)	(A) or	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securit Following Reported (Instr. 3 and 4)		s) C	orm:	Beneficial	
					(Month/		Code	V Amoun	(A) or (D) P	rice			o (1	Direct (D) (Cor Indirect (I) (Instr. 4)	1
								this form are currently val	e not required lid OMB cont			form disp	olays a		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of		3A. Deemed Execution Date, if	4. Transac Code	z., pu etion	5. Number Derivative Acquired Disposed	r of e Securities (A) or of (D)	currently val	f, or Beneficial ible securities) sable and te	rol number	Amount of Securities	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially	Ownershi Form of Derivativ	11. Natur of Indirec Beneficia oe Ownershi
Derivative Security	Conversion or Exercise	Date	3A. Deemed Execution Date, if any	4. Transac Code	z., pu etion	5. Number Derivative Acquired	r of e Securities (A) or of (D)	ed, Disposed o otions, converti 6. Date Exerci Expiration Date	f, or Beneficial ible securities) sable and te	7. Title and Underlying	Amount of Securities	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities	Ownershi Form of Derivativ Security: Direct (D or Indirect	of Indirect Beneficia Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative Security	Date	3A. Deemed Execution Date, if any	4. Transac Code (Instr. 8	etion	5. Number Derivative Acquired Disposed (Instr. 3, 4	rarrants, op r of e Securities (A) or of (D) o, and 5)	ed, Disposed o ottons, converti 6. Date Exerci Expiration Dat (Month/Day/Y	f, or Beneficial ible securities) sable and te (ear) Expiration Date	7. Title and Underlying (Instr. 3 and	Amount of Securities (4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivativ Security: Direct (D or Indirect)	of Indirect Beneficia Ownershi (Instr. 4)
Derivative Security (Instr. 3) Convertible Promissory	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transac Code (Instr. 8	etion	5. Number Derivative Acquired Disposed (Instr. 3, 4	rarrants, op r of e Securities (A) or of (D) o, and 5)	currently val ed, Disposed o bitions, converti 6. Date Exerci Expiration Dat (Month/Day/Y Date Exercisable 01/08/2019	f, or Beneficial ible securities) sable and te (ear) Expiration Date	7. Title and Underlying (Instr. 3 and Title	Amount of Securities (4) Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownershi Form of Derivativ Security: Direct (D or Indirect) (I) (Instr. 4)	of Indirect Beneficia Ownershi (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Klump Michael A 1111 MAIN STREET, SUITE 660 VANCOUVER, WA 98660	X				

Signatures

/s/ Michael D. Mulholland, as attorney-in-fact	01/08/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reported securities of CytoDyn Inc. (the "Company") are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited (1) liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein
- The Company recently completed a convertible promissory note exchange offer in which Argonne Trading participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the "Original Note") beneficially owned by Mr. Klump, the Company (i) issued a new convertible promissory note in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.	